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Abstract
Background: Epigallocatechin-3-gallate (EGCG) has been demonstrated to inhibit cancer in experimental studies
through its antioxidant activity and modulations on cellular functions by binding specific proteins. We
demonstrated previously that EGCG upregulates the expression of microRNA (i.e. miR-210) by binding HIF-1a,
resulting in reduced cell proliferation and anchorage-independent growth. However, the binding affinities of EGCG
to HIF-1a and many other targets are higher than the EGCG plasma peak level in experimental animals
administered with high dose of EGCG, raising a concern whether the microRNA regulation by HIF-1a is involved in
the anti-cancer activity of EGCG in vivo.
Results: We employed functional genomic approaches to elucidate the role of microRNA in the EGCG inhibition of
tobacco carcinogen-induced lung tumors in A/J mice. By analysing the microRNA profiles, we found modest
changes in the expression levels of 21 microRNAs. By correlating these 21 microRNAs with the mRNA expression
profiles using the computation methods, we identified 26 potential targeted genes of the 21 microRNAs. Further
exploration using pathway analysis revealed that the most impacted pathways of EGCG treatment are the
regulatory networks associated to AKT, NF-B, MAP kinases, and cell cycle, and the identified miRNA targets are
involved in the networks of AKT, MAP kinases and cell cycle regulation
Conclusions: These results demonstrate that the miRNA-mediated regulation is actively involved in the major
aspects of the anti-cancer activity of EGCG in vivo.
Background
The consumption of green tea, a beverage derived from
the dried leaves of the Camellia sinensis plant, has a
long history in Asian countries and is becoming more
popular in Western nations. Accumulated data has sug-
gested that the consumption of green tea is beneficial to
human health, and some of the benefits are supported
by results from the experimental studies. In particular,
the cancer preventive activity of green tea has been
extensively investigated and demonstrated in many
organ sites in different animal models and cell line sys-
tems [1,2]. The most abundant and active anti-cancer
constituent in green tea is (-)-epigallocatechin-3-gallate
(EGCG). EGCG and other tea catechins are also referred
to as green tea polyphenols for their carrying multiple
phenolic groups with the ability to trap reactive oxygen
species (ROS). Substantial studies have been conducted
to uncover the cancer preventive mechanism of EGCG
at the cellular and molecular levels. The results from
these studies suggest that the treatment with EGCG or
EGCG-rich tea extract leads to a wide range of
responses, and the cancer prevention activity is likely to
be mediated through multiple mechanisms that are a
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result of EGCG’s direct scavenging of ROS and/or its phy-
sical interactions with specific proteins to modulate gene
expression and cellular signaling. The effects of EGCG
include the increment in detoxification capacity to prevent
carcinogen-induced cellular damages [3-5], alteration in
epigenetic modifications such as reducing the DNA hyper-
methylation-induced silencing of tumor suppressor genes
[6-11], inhibition on tumor cell growth by inducing cell
cycle arrest and apoptosis [2,12], anti-inflammation
[4,13,14], and inhibition on tumor-associated angiogenesis
[2,12,15].
However, most experimental evidences supporting anti-
cancer mechanisms of green tea polyphenols including the
ones mentioned above are mainly obtained from in vitro
studies, and whether these mechanisms play significant
roles in the cancer prevention/inhibition in vivo are largely
unknown. To clarify this issue, studies using experimental
animals are necessary. One well-characterized animal
model used is the tobacco carcinogen-induced lung carci-
nogenesis in A/J mice. It has been shown by using this ani-
mal model that tumor multiplicity and size are effectively
inhibited when mice are fed on a diet containing EGCG
[2,16]. A/J mice treated with tobacco carcinogen such as
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) or
benzo[a]pyrene (B[a]P) develop lung adenoma within 20
weeks, and these tumors begin to progress to adenocarci-
noma after 20 weeks [17-19]. When 0.5% green tea poly-
phenol extract was given to the NNK-treated A/J mice as
drinking fluid for 32 weeks, the progression of adenoma to
adenocarcinoma was inhibited [19]. This result was consis-
tent with EGCG inhibiting the growth of the xenograft
tumors of human lung cancer cell lines H1299 and H460
in nude mice [20]. In these in vivo studies, apoptosis was
induced and pro-proliferation signaling (i.e. c-Jun and
phospho-ERK1/2) were reduced in tumors, but not in nor-
mal lung tissues, after EGCG treatment [19,20]. Differen-
tial gene expressions have been profiled in the tumors
from NNK- and B[a]P-treated mice fed on diet with or
without green tea polyphenol extract for 20 weeks. Cell
cycle regulation and inflammation were found to be the
most impacted pathways by EGCG [21], suggesting that
the anti-cancer activity of green tea polyphenols is
mediated by inhibiting cell proliferation and anti-inflam-
mation. These inhibitions are likely to be combinatory
effects resulted from changes in the expressions of multi-
ple genes induced by the green tea polyphenols [21].
An effective mechanism to regulate multiple classes of
genes is through small regulatory RNAs called micro-
RNAs (miRNAs) [22,23]. MiRNA exerts very fine-tune
regulation on the expression of most protein-coding
genes to optimize their expressions [22,23]. Upon bind-
ing to its target mRNA, miRNA can activate the Argo-
naute-catalyzed targeted cleavage of mRNA [24]; thus,
miRNA predominantly acts to reduce the targeted
mRNA [25]. Because miRNA recognizes the short seg-
ment usually in the 3’ untranslated region of mRNA
with imperfect complementarity, one miRNA is able to
recognize a set of short RNA motifs featured with a
common 5’-end sequence and variable 3’-end sequence,
which increases the magnitude of the numbers of genes/
mRNAs targeted by a miRNA [22,26]. Cellular miRNA
pool forms a hierarchical regulatory network that is
associated with cell identity and function, and the
miRNA expression profile can be reset when the cell
identity changes during development, differentiation,
environmental challenge, and tumorigenesis [27]. In
lung development, miRNA has been demonstrated to
play critical roles. Different groups of miRNAs are
expressed in developing and mature lung tissues, sug-
gesting the distinct roles of these miRNAs in regulating
cell growth and differentiation of lung tissue as well as
maintaining normal lung functions [28]. For example,
the miR-17-92 cluster promotes the proliferation of lung
progenitors [28], whereas miR-34c, miR145, and miR-
142-5p suppress lung cell growth [29]. In lung tumori-
genesis, there are also evidences supporting the critical
roles of miRNA. For example, miR-34c, miR145, and
miR-142-5p, which suppress lung cell growth, are found
to be repressed in both human and mouse lung cancer
[29]. Furthermore, the overall miRNA levels in the
oncogenic K-ras-induced mouse lung cancer are found
to be reduced [30], which is consistent with the finding
that lung-specific knockout of Dicer results in the
abnormality of lung development and function [31].
Since the 22 base-active miRNA is initially expressed in
a larger precursor fragment called pre-miRNA and is
generated through the maturation process mediated by
Dicer [32], there is no mature functional miRNA with-
out Dicer. These data suggest that Dicer is a haploinsuf-
ficient tumor suppressor gene in lung, and the
optimized level of miRNA is necessary to maintain the
normal lung cell functions and phenotype [33].
Since we and others have demonstrated that EGCG can
prevent lung carcinogenesis and inhibit lung cancer
growth [2], we explored whether the cellular changes in
lung cancer cells treated with EGCG are associated with
alteration in miRNA expression. By studying the miRNA
profiles in mouse and human lung cancer cells treated
with EGCG, we found that the upregulation of miR-210 is
the predominant miRNA event in response to the EGCG
treatment, resulting in the reduced proliferation and
anchorage-dependent growth [34]. This finding provides
the evidence to support the importance of miRNA in the
anti-cancer activity of EGCG. However, the upregulation
of miR-210 by EGCG in the cultured lung cancer cell lines
required higher concentration (i.e. over 20 μM) of EGCG
than the highest plasma peak level (i.e. ~10 μM) detected
in humans or animals administered with high dose of
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EGCG [2,35,36]. This raises a concern whether such a
mechanism is effective in vivo, although a wide range of
doses (i.e. 0.1-100 μM) are commonly used in the in vitro
studies. In this study, in order to determine whether miR-
NAs such as miR-210 are involved in the cancer inhibition
by EGCG in vivo, we employed the NNK-induced lung
carcinogenesis in A/J mice fed on a diet with or without
EGCG for miRNA and mRNA profile studies. Since the
most effective inhibition induced by the EGCG treatment
in this animal model is the inhibition of progression from
adenoma to adenocarcinoma [19], one of the best win-
dows to study the relevant EGCG-induced miRNA and
mRNA profiles is on the adenoma cells before their pro-
gression to adenocarcinoma. Thus, the A/J mice were first
treated with NNK to induce adenoma. After 19 weeks, the
mice were fed a diet with or without EGCG for a short-
term (i.e. one week) in order to study the miRNA and
mRNA profiles before the progression. By using genomic
and bioinformatics approaches to analyse the generated
mRNA profiles, we uncovered that the most impacted
pathways by the EGCG treatment are the networks related
to AKT, NF-B, MAP kinases, and cell cycle regulation.
Through the miRNA profiles, we identified a group of
miRNAs responsive to EGCG, and we further found that
the potential targets of these miRNAs include genes in the
regulatory networks of AKT, MAP kinases and cell cycle
regulation. Such discoveries demonstrated that the regula-
tion of miRNA is part of the anti-cancer activity of EGCG
in vivo.
Results
Treatment with EGCG induces changes in miRNA
expression in the NNK-induced mouse lung tumor
We previously studied the miRNA expression profiles in
response to the EGCG treatment using human and
mouse lung cancer cell lines and found that the upregu-
lation of miR-210 is the predominant miRNA event
responding to the EGCG treatment and the overexpres-
sion of miR-210 inhibits lung cancer cell proliferation
[34]. The upregulation of miR-210 by EGCG was
demonstrated to be mediated through the stabilization
of HIF-1a by EGCG. The Kd of the EGCG binding to
HIF-1a is 3.47 μM [34], which is compatible to the
highest plasma peak EGCG level (i.e. 7-10 μM) in the
experimental animals administered with diet containing
high dose of EGCG [2,35], suggesting the possibility that
miR-210 may play a role inhibiting lung cancer in vivo.
However, what concentration can be reached inside the
cells and whether the duration is long enough to lead to
physiological significance remains to be unclear. Herein,
to address this possibility, we employed the NNK-
induced lung carcinogenesis in A/J mice to study the
miRNA profiles in mice fed on the control and EGCG
diets in an effort to evaluate the role of miR-210 and
other miRNAs in vivo. We treated 30 female A/J mice
with NNK to induce lung adenoma according to pre-
viously established procedure [19]. At 19 weeks after the
first NNK injection when the adenoma is expected to be
induced at 100% incidence and readily to progress to ade-
nocarcinoma, mice were randomly separated into the
control and EGCG treatment groups (15 per group).
While the control groups remained on AIN93M diet, the
EGCG treatment group received 0.4% EGCG in diet for 1
week (Figure 1A). We expect that through this short-
term treatment, the EGCG-treated adenomas would
undergo some responses including changes in the expres-
sion of some genes that play a role in the EGCG-induced
cancer inhibition. At the endpoint, we excised the tumors
from lung under dissecting microscope, and obtained
high quality and quantity RNAs from 8 control and 8
EGCG-treated samples. These samples were first used for
the miRNA microarray to obtain the miRNA profiles.
We conducted cluster analysis on the miRNA profiles
and found that these 16 samples can be separated into
Figure 1 A. Illustration of the animal experiment schedule.
B. Heat map of the cluster analysis of the miRNA profiles of the
NNK-induced mouse lung tumors in the A/J mice fed on the
control (C1-8) and EGCG diet (E1-E8).
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three major clusters: all controls except C5 were in one
cluster (control cluster), control C5 and 3 EGCG-treated
samples (E1, E2, and E7) were in one cluster that is rela-
tively close to the control cluster, and the rest 5 EGCG-
treated samples were in the other cluster (responsive
cluster) (Figure 1B). Since E1, E2 and E7 were between
control and responsive groups, they represented a weak
responsive group. Such a distribution actually presented
the different responses of individual mice although we do
not know what caused the difference.
By analysing the difference between the control and
treatment groups (all 16 samples), we found 5 miRNAs
were upregulated by at least 1.0 fold (P-value ≤ 0.01) and
no miRNA was downregulated by at least 1.0 fold (P-value
≤ 0.01) in response to the EGCG treatment (Table 1). If
we reduced the selection condition to 0.5 fold change, it
was found that 12 miRNAs were upregulated in response
to the EGCG treatment (the expression level is 1.5 fold or
above (≥1.5) of the controls and P-value ≤ 0.01) (Table 1),
and 9 miRNAs were downregulated (the expression level
is 0.75 fold or lower (≤0.75) of the controls and P-value ≤
0.01) (Table 2). When we excluded the 3 weak responsive
samples from the treatment group and performed the
same comparison between the 8 controls and the 5
responsive treatment samples, the result remained the
same, suggesting that the identified EGCG-regulated miR-
NAs are the predominant events. To our surprise, miR-
210, found upregulated by EGCG in in vitro experiment,
ranks right behind the 12 upregulated miRNAs in this in
vivo study (Table 1), but it was excluded because the large
associated P-value indicates that its upregulation may not
be statistically significant in all samples. By examining the
raw data, miR-210 in the treatment group is upregulated
about 1.44 fold and the associated P-values are 0.04 and
0.15 in the two comparisons using the 8 and 5 treatment
samples respectively. This, however, might suggest that
some animals did not intake sufficient EGCG to reach the
level required for the activation of miR-210. Thus, the regu-
lation of miR-210 by EGCG is unlikely to play a significant
role in vivo in all animals at the dose used in this experi-
ment. On the other hand, using miR-210 as the reference,
we believe that the 12 upregulated miRNAs in Table 1
which ranked higher than miR-210 and are ubiquitously up
in all samples with a P-value less than 0.01, are high confi-
dent miRNAs targeted by EGCG, and the 9 downregulated
miRNAs in Table 2 that are identified by the same stan-
dards are also the targets with high confidence.
Treatment with EGCG induces changes in mRNA
expression in the NNK-induced mouse lung tumor
To explore the roles of the EGCG-responsive miRNAs,
we next aimed at uncovering the miRNA targeted genes.
For this purpose, we selected RNA samples from 3 con-
trols and 3 responsive samples for the mRNA microar-
ray and obtained the mRNA expression profiles. By
analysing the differentially expressed mRNA between
the control and the EGCG-treated (with the condition
of ≥1.0 fold change and P-value ≤ 0.01), we found that
there were 295 and 71 mRNAs up- and down-regulated,
respectively (Additional file 1 and Additional file 2), in
response to the EGCG treatment. To understand the
impact of these genes on the cellular functions, we ana-
lysed the functional associations of these 366 genes
using Ingenuity Pathway Analysis. The result showed
that the top associated functions of these genes include
the regulation of morphology, movement, inflammation,
Table 1 The EGCG-upregulated miRNAs in the NNK-induced A/J mouse lung tumor.
miRNA name (Release 17)† Accession Number miRNA name (Release 20)† Fold Changes P-Value (8)‡ P-Value (5)ǁ FDR (8)‡
mmu-miR-2137 MIMAT0011213 mmu-miR-2137 2.88 2.37E-07 1.24E-03 1.55E-04
mmu-miR-449a MIMAT0001542 mmu-miR-449a-5p 2.47 2.21E-03 9.74E-03 5.79E-02
mmu-miR-144 MIMAT0000156 mmu-miR-144-3p 2.30 8.95E-04 3.06E-03 3.67E-02
mmu-miR-486# MIMAT0003130 mmu-miR-486-5p 2.10 6.79E-04 1.89E-03 3.18E-02
mmu-miR-3107# MIMAT0014943 mmu-miR-3107-5p 2.10 6.79E-04 1.89E-03 3.18E-02
mmu-miR-193 MIMAT0000223 mmu-miR-193a-3p 2.08 9.64E-03 2.21E-02 1.66E-01
mmu-miR-5130 MIMAT0020641 mmu-miR-5130 1.82 1.01E-04 6.02E-03 9.42E-03
mmu-miR-2861 MIMAT0013803 mmu-miR-2861 1.75 1.89E-05 1.45E-03 2.48E-03
mmu-miR-511-3p MIMAT0017281 mmu-miR-511-3p 1.64 1.67E-02 6.86E-02 2.06E-01
mmu-miR-763 MIMAT0003896 mmu-miR-763 1.57 1.02E-03 9.37E-03 3.75E-02
mmu-miR-3473 MIMAT0015645 mmu-miR-3473a 1.56 4.12E-03 1.78E-02 9.00E-02
mmu-miR-211* MIMAT0017059 mmu-miR-211-3p 1.53 1.19E-04 2.64E-03 9.73E-03
mmu-miR-210 MIMAT0000658 mmu-miR-210-3p 1.44 3.92E-02 1.59E-01 3.52E-01
† Based on http://www.mirbase.org
‡ Comparison includes all 8 controls and all 8 EGCG-treatment samples.
щComparison includes all 8 controls and 5 responsive EGCG-treatment samples.
# These 2 miRNAs, miR-486 and miR-3107, are recognized by the same probe.
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development and proliferations (Figure 2), which are the
relevant functions in tumor growth, progression, and
metastasis. Further analysis revealed 18 pathways, and
the top 4 relevant pathways are in the networks centra-
lized by AKT, NF-B, MAP kinases and cell cycle regu-
lators (Additional files 3, 4, 5, 6), supporting the roles of
EGCG in cell proliferation inhibition and anti-inflamma-
tion. Targeting these networks by EGCG are actually
consistent with the literature supporting the roles of
EGCG in inhibiting cell cycle and inflammatory
response (reviewed in [2,37]). Indeed, a previous study
using green tea polyphenol diet to treat A/J mice bear-
ing the NNK-induced lung tumor for 20 weeks, a long
term treatment, also revealed the modulation on the cell
cycle: a group of 88 genes were identified as the respon-
sive genes and a major associated network of these 88
genes was the cell cycle regulation [21]. Therefore, in
both short- and long-term treatments, the inhibition on
cell proliferation is the common mechanism.
EGCG regulates cellular functions mediated through its
regulations on miRNAs
We identified the expression changes of the 21 miRNAs in
the NNK-induced lung tumor in response to the EGCG
treatment in the above study. While we did not obtain evi-
dence to support the role of miR-210 that is upregulated
in the in vitro cultured lung cancer cells treated with
EGCG, these 21 miRNAs represent the ones that are
involved in the in vivo mechanisms of the EGCG inhibi-
tion of lung cancer. To explore the roles of these miRNAs
in the EGCG-treated lung tumor, we used the computa-
tional approach to identify the potential targets of these
miRNAs and correlated the predicated targets with the
mRNA profiles based on the principal that miRNA down-
regulates its targeted mRNA. By using three highly confi-
dent and commonly used miRNA target prediction
computation programs [38] as described in the Methods,
we identified a group of 26 genes that are predicated to be
the targets of the EGCG-regulated 21 miRNAs, and the
changes of their expression levels are inversely correlated
to the changes of miRNAs (Table 3). To evaluate the roles
of these miRNA targeted genes, we performed Ingenuity
Pathway Analysis for these 26 genes and revealed an inter-
action network that is centralized by IGFBP5 and is
involved in the regulation of AKT and ERK1/2 (Additional
file 7). This network includes some players in the networks
of AKT, MAP kinase, and cell cycle regulation, which was
identified as the top functional networks regulated by
EGCG. Therefore, this result indicates that miRNA is
involved in the major pathways of the anti-cancer activity
of EGCG in vivo.
Discussion
In this study, we used the functional genomic approaches
to explore the gene regulation mediated through miRNAs
in response to the EGCG treatment in mouse lung tumor.
We identified 21 miRNAs whose expressions are regulated
by EGCG. By analysing the functional ontology of the
Table 2 The EGCG-downregulated miRNAs in the NNK-induced A/J mouse lung tumor.
miRNA name (Release 17)† Accession Number miRNA name (Release 20)† Fold Changes P-Value (8)‡ P-Value (5)ǁ FDR (8)‡
mmu-miR-696 MIMAT0003483 mmu-miR-696 0.54 2.66E-03 3.65E-02 6.33E-02
mmu-miR-449c MIMAT0003460 mmu-miR-449c-5p 0.58 2.70E-06 9.81E-04 8.86E-04
mmu-miR-7a MIMAT0000677 mmu-miR-7a-5p 0.60 1.67E-03 3.66E-03 5.12E-02
mmu-miR-205 MIMAT0000238 mmu-miR-205-5p 0.62 3.03E-01 3.86E-03 7.56E-01
mmu-miR-450a-2* MIMAT0004789 mmu-miR-450a-2-3p 0.63 1.00E-04 7.93E-03 9.42E-03
mmu-miR-1199* MIMAT0017333 mmu-miR-1199-3p 0.63 1.40E-04 1.10E-02 1.02E-02
mmu-miR-374c MIMAT0014953 mmu-miR-374c-5p 0.63 8.79E-03 1.62E-02 1.56E-01
mmu-miR-218 MIMAT0000663 mmu-miR-218-5p 0.64 1.72E-03 3.82E-03 5.12E-02
mmu-let-7b* MIMAT0004621 mmu-let-7b-3p 0.66 4.01E-04 4.74E-03 2.19E-02
† Based on http://www.mirbase.org
‡ Comparison includes all 8 controls and all 8 EGCG-treatment samples.
щComparison includes all 8 controls and 5 responsive EGCG-treatment samples.
Figure 2 Gene functional associations by Gene Ontology (GO)
analysis of the changes in the mRNA expression profile in
response to the EGCG treatment.
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potential targets of these 21 miRNAs, we found that the
target genes include the key components in the signaling
regulation pathways centralized with AKT, MAP kinase,
and cell cycle regulators. Since these pathways play impor-
tant roles in carcinogenesis, our results support the impor-
tance of miRNA in the cancer inhibition by EGCG in vivo.
By using genomic and bioinformatics approaches to ana-
lyse the mRNA profiles, we found that the EGCG-induced
expression profile change in vivo constitutes regulatory
networks which impact cellular signalings involving AKT,
NF-B, MAP kinases, and cell cycle regulation, consistent
with the well-characterized inhibitions on proliferation
and inflammation by EGCG. The inhibition on cell prolif-
eration by EGCG has been demonstrated in different can-
cer cells and animal models [2,12,37]. Particularly, our
data is consistent with our previous finding that the pro-
proliferation signalling, such as the activation of MAP
kinase (i.e. phospho-ERK1/2), was significantly reduced in
tumor tissues but not in normal lung tissues after EGCG
treatment [19,20]. The regulation on AKT signaling has
been reported in many studies to be through various
mechanisms including the direct downregulation of AKT
mRNA and inhibition of AKT activation as well as the
indirect inhibition of upstream signaling such as the activa-
tions of receptor tyrosine kinases, c-Met, EGFR and IGFR
[2,12,37,39]. We did not find the expression level change in
AKT, but our data rather suggested that the effect on AKT
could be resulted from multiple mechanisms simulta-
neously. The regulation on NF-B is also consistent with
previous findings that EGCG displays anti-inflammation
Table 3 Genes regulated by EGCG potentially mediated through miRNA.
mRNA coding Genes Targeted by miRNA
Gene Name Changes in expression level miRNA name (Release 20) Changes in expression level





AMMECR1 down mmu-miR-144-3p Up
ANKRD34B down mmu-miR-511-3p Up
ART3 up mmu-miR-374c-5p Down





Cd19 up mmu-miR-450a-2-3p down
CENPF down mmu-miR-211-3p Up
cnr1 up mmu-miR-374c-5p down
DCN up mmu-miR-374c-5p down
EFNA5 up mmu-miR-374c-5p down




ELOVL6 up mmu-miR-374c-5p down
IGFBP5 up mmu-miR-450a-2-3p down




PER2 down mmu-miR-211-3p Up
per3 down mmu-miR-3068-3p Up
pfn2 up mmu-miR-7a-5p down
rbm24 up mmu-miR-374c-5p down
RBPMS2 up mmu-mir-205-5p down
SYNPO2 up mmu-let-7b-3p down
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activity through inhibiting the inflammatory response mas-
ter regulator NF-B [12]. Like the regulation on AKT, the
network reveals that NF-B can be influenced by multiple
pathways induced by EGCG: blocking the activation of NF-
B by quenching ROS [40], inhibiting the upstream regula-
tors such as PI3K/Akt and MAP kinases [12], or inhibiting
Pin1, a NF-B chaperon protein [41]. However, the mRNA
profile analysis did not find evidence for the involvement
of pro-apoptosis and anti-angiogenesis, though both of
which are demonstrated in other studies as the cancer inhi-
bition mechanisms of EGCG [2,37]. Actually, the pro-
apoptosis and anti-angiogenesis were not found in the
mRNA profile analysis in the study using the long-term
EGCG treatment either [21]. There are several possibilities
that these two mechanisms were not identified by the
expression profile analyses. First, the caspase-mediated
initiation of apoptosis acts through the proteinase-
mediated signaling cascade which can be independent of
transcriptional activation or suppression. Second, the
endothelial cells are accounted only for a small fraction in
the tumors and the related changes are too weak to be
recognized. Third, the dose of EGCG used in this study
might not reach the effective level to cause these actions.
Nevertheless, the miRNA and mRNA expression profile
analysis provides trustworthy data to support that the in
vivo mechanism of cancer inhibition of EGCG, and the
identified targeted pathways are consistent with the data in
the literature.
The major goal of this study was to explore the roles
of miRNA in the anti-cancer activity of EGCG in vivo.
We found that the EGCG-regulated miR-210 identified
in our previous in vitro study [34] is upregulated to 1.44
fold with a large P-value, indicating the lower confi-
dence on the upregulation of miR-210 in this study.
Instead, we identified 21 miRNAs with high confidence.
But the levels of these 21 miRNAs were not found to be
regulated by EGCG in the cultured lung cancer cell
lines, including CL13 mouse lung cancer cell line
derived from the NNK-induced mouse lung cancer [18]
in our previous study [34]. The discrepancy could be
resulted from the differences in the levels of the oxida-
tive stress and EGCG-binding proteins between primary
tumor and the in vitro cultured cells. For example, the
antioxidant activity of EGCG might play more important
roles in the in vitro cultured cells that are usually
exposed to higher levels of oxidative stress than in pri-
mary tissues [42]. Another possibility could be due to
that the effective action of EGCG is on the adenoma
progression to adenocarcinoma [19], and adenoma are
the targeted cells in our current study whereas lung can-
cer cell lines are derived from advanced cancers (i.e.
invasive adenocarcinomas). In addition, we cannot com-
pletely exclude the possibility that these changes take
place in non-cancer cells. However, it seems unlikely
because the majority of the cells in the isolated lung
tumor tissues are dysplastic adenoma cells [18,19]. No
matter what caused the difference between the in vivo and
in vitro studies, our finding of the 21 EGCG-regulated
miRNAs in this in vivo study strongly supports the impor-
tance of the use of experimental animals in the exploration
of the anti-cancer mechanism of EGCG. Our result also
supports that functional genetic and proteomic analysis is
an effective approach to uncover the systematic responses
in a complicated system such as primary tumor.
One long-standing unanswered question in the field is
whether the cancer inhibition by EGCG in vivo is
mediated by the mechanisms that are identified in the
in vitro studies in which higher concentrations of EGCG
(e.g. 50-100 μM) are commonly used. EGCG could tar-
get multiple pathways through different direct binding
proteins [2]. In our previous study in which the miR-
210 was identified as the major EGCG-regulated
miRNA, we demonstrated the direct binding of EGCG
to HIF-1a [34]. However, these direct binding proteins
are targeted by EGCG at a wide range of binding affi-
nities [35]; thus, the cellular functions targeted by
EGCG are largely dependent on the doses used in the
experiments. In most cases, to be effective in vitro,
higher concentration of EGCG such as 20-100 μM are
required. In contrast, the maximum plasma peak levels
of EGCG in human and animal models administered
with higher doses through drinking or diet is less than
10 μM [2,35]. The plasma concentration of EGCG is
probably the most important factor in evaluating the
working mechanism of EGCG in vivo. For example, the
affinity for EGCG to bind HIF-1a is about 4.7 μM. To
activate HIF-1a for upregulating miR-210 in the cul-
tured lung cancer cells so as to produce significant
effect, at least 20 μM EGCG in the culture medium is
required [34], suggesting that a higher concentration of
EGCG is necessary to reach the effective concentration
inside the cells through free diffusion. Although we can-
not exclude the cases that EGCG can function on the
cell surface, be transported into cells by a transporter,
or reach higher concentration in local tissues than the
plasma level, a mechanism that requires higher dose
should be further evaluated using the in vivo experi-
ment. In this study, by analysing the profiles of miRNAs
and mRNAs in the NNK-induced lung tumors in A/J
mice fed on EGCG, we found that there was modest
upregulation of miR-210 (an increase to 1.44 fold on
average after the EGCG treatment). However, such
upregulation of miR-210 manifests large differences
among individual mice. Such differences might be due
to that some mice failed to intake sufficient EGCG to
reach the required level. Thus, this data suggests that
miR-210 is unlikely to play a critical role in the EGCG-
induced lung cancer inhibition in vivo.
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The miRNA targeted genes were identified by the combi-
nation of computation method and the correlated expres-
sion changes in miRNAs and mRNAs. Indeed, the miRNA
target identification traditionally relies on the computation
method because the involved genomic information is too
large to be easily handled via the experimental study [38].
Based on the validation using the genome-wide experimen-
tal studies, the computation predictions have been proven
to be reliable with high confidence [43,44]. However, the
rates of the false positive and negative calls remain high for
each method. To overcome this pitfall, multiple predication
methods were used to reduce the false calls. Since the next
generation sequencing technology is well-developed and the
related cost is reducing, the real target genes of a specific
miRNA in a given context can be identified by sequencing
the RNA products generated using the immunoprecipitated
Argonaute protein-RNA complex [45]. Thus, a future study
on the identification of the miRNA target genes using
experimental approaches to validate our findings is under
consideration.
Conclusion
We demonstrated, for the first time, that EGCG induces
miRNA profile changes in the NNK-induced A/J mouse
lung tumor. The targeted genes of these miRNAs are
involved in the regulatory network that plays an impor-
tant role in the anti-cancer activity of EGCG in vivo.
Furthermore, this in vivo study provides valuable data
that is different from the result obtained from the in
vitro studies, which further emphasizes the importance
of animal models in the evaluation of cancer inhibitory
mechanism of EGCG.
Methods
Animal experiment and treatment
Mouse lung carcinogenesis was induced by NNK in the
susceptible A/J mice as described previously [19]. The
experimental procedures were conducted in accordance
to the animal protocol (Protocol No. 91-024) approved
by the Animal Care and Facilities Committee of Rutgers,
the State University of New Jersey. Thirty female A/J
mice at the age of 4 weeks were purchased from the
Jackson Laboratory (Bar Harbor). After arrival at the
animal facility, mice were housed in the room at room
temperature (20 ± 2°C) with a relative humidity of 50 ±
10% and with an alternating 12 h light/dark cycle
throughout the duration of the study. One week later,
mice diet was switched from lab chow to the purified
AIN93M diet (Research Diet), the standard purified
rodent diet with the defined nutrients by American
Institute of Nutrition (AIN) committee. At the age of
6 weeks, mice were treated with a dose of NNK (100 mg/
kg body weight, i.p.) (Chemsyn Science Laboratories)
(Figure 1A). After a week, mice were treated with another
dose of NNK (100 mg/kg body weight, i.p.). Mice were
monitored daily during and after the treatments. At 19
weeks after the first NNK injection, mice were separated
randomly into 2 groups (15 mice per group): one group
remained on the AIN93M diet as the control, and the
other group was fed the purified diet containing 0.4%
EGCG (prepared by Research Diet) as the treatment.
EGCG (94% purity) was a gift from Dr. Yukihiko Hara
(Mitsui Morin Co.). After one week of the EGCG treat-
ment, both groups of mice were sacrificed by CO2 asphyx-
iation and the lungs were removed. One leaf of lung from
each mouse was inflated by PBS and fixed in 10% buffered
formalin for pathology analysis. Visible tumors in the rest
of lung tissue were carefully separated from the adjacent
normal lung tissues under dissecting microscope and
stored in RNAlater Solution (Ambion) at -80°C for RNA
extraction. Because these tumors were very small (nor-
mally 0.1-0.3mm in diameter), we combined all tumors
(an average of 20 per mouse) from one mouse as one
sample.
RNA purification and microarray analyses
Total RNA was purified from the tumor samples stored
in RNAlater Solution using the miRNeasy kit (Qiagen)
according to the manufacturer’s protocol once the
development of adenomas were validated by the histo-
pathological analysis. Based on the quality and quantity
of the total RNA samples, RNA samples from 8 mice
fed on the controls diet and 8 on the 0.4% EGCG diet
were used for the miRNA profiling. To obtain the
miRNA expression profiles, miRNA samples were ana-
lyzed by the miRNA microarray conducted by Ocean
Ridge Biosciences using Multispecies MicroRNA Array
Chip covering miRBase Release 17.0. Data collection
and analysis were also conducted by Ocean Ridge Bios-
ciences using the standard method for microarray analy-
sis. Briefly, for the data normalization, the normalization
factor (N) for each microarray was obtained by the 20%
trim mean of the species (human/mouse) probes intensi-
ties above threshold in all samples. The log2-transformed
spot intensities for all probe features on the array were
normalized by subtracting N from each spot intensity
and scaled by adding the grand mean of N across all
microarrays. P-value and false discovery rate (FDR) were
calculated for all samples.
The mRNA expression profiles of 3 controls and 3
EGCG-treated samples were analysed by microarray
using Affymetrix GeneChip Mouse Gene 1.0 ST Array
by Functional Genomics Core at Cancer Institute
of New Jersey. Data collection and analysis were also
performed by the core according to Affymetrix array
standard procedure.
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Bioinformatics analyses
The differential expressions of miRNA in tumors from
mice on the control AIN93M diet or the 0.4% EGCG diet
were analyzed by the Ocean Ridge Biosciences as
described above. Briefly, the differentially expressed miR-
NAs were ranked by the smallest P-value and FDR value
and then by the fold of change. The differential expres-
sions of mRNA were analyzed using the BRB-Array Tool
v4.4 beta 1 http://linus.nci.nih.gov/BRB-ArrayTools.html
with the normalization by reference for single channel
data. For the mRNA microarray data, the up- or down-
regulated genes are defined to be those whose mRNA
expression levels were increased or decreased in all three
EGCG-treated samples compared to three controls and
the average change must be at least 1.0 fold. P-value and
FDR were calculated for all samples.
The potential target genes of a specific miRNA were
identified using three common computation programs
that are proved to predict the miRNA targets with bet-
ter accuracy based on proteomic data [38]: miRDB
(http://mirdb.org/miRDB/; [46,47]), Diana microT v3.0
(http://diana.cslab.ece.ntua.gr/microT/; [48,49]), and
TargetScan 5.2 for mouse http://www.targetscan.org/
mmu_50/. Only the gene which was identified as a can-
didate of a specific miRNA by at least two programs
was classified as the candidate target gene. The candi-
date target genes were further identified as the miRNA
target by the correlation of the expression level changes
found in the miRNA and mRNA expression profiles; the
up- or down-regulation in the mRNA expression level
of a target gene should correspond to the opposite
miRNA change.
To sort out the most impacted cellular functions, we
loaded the overall differentially expressed genes and the
identified miRNA targets to the Ingenuity Pathway Ana-
lysis http://www.ingenuity.com for further pathway
analyses.
Additional material
Additional File 1: The EGCG-upregulated mRNAs in the NNK-induced A/
J mouse lung tumor
Additional File 2: The EGCG-downregulated mRNAs in the NNK-induced
A/J mouse lung tumor
Additional File 3: Top impacted pathway centralized with the
regulation of AKT by the EGCG-induced genes in the NNK-induced
mouse lung tumors. Shadowed shapes represent the EGCG targeted
genes. Dashed lines represent the indirect interactions. The arrows
represent the interaction directions.
Additional File 4: Top impacted pathway centralized with the
regulation of NF-B and cytokines/chemokines by the EGCG-induced
genes in the NNK-induced mouse lung tumors. Shadowed shapes
represent the EGCG targeted genes. Dashed lines represent the indirect
interactions. The arrows represent the interaction directions.
Additional File 5: Top impacted pathway centralized with the cell cycle
regulators by the EGCG-induced genes in the NNK-induced mouse lung
tumors. Shadowed shapes represent the EGCG targeted genes. Dashed
lines represent the indirect interactions. The arrows represent the
interaction directions.
Additional File 6: Top impacted pathway centralized with the
regulation of MAP kinase ERK by the EGCG-induced genes in the NNK-
induced mouse lung tumors. Shadowed shapes represent the EGCG
targeted genes. Dashed lines represent the indirect interactions. The
arrows represent the interaction directions.
Additional File 7: The impacted pathway by the EGCG-induced miRNA
targets in the NNK-induced mouse lung tumors is centralized with
IGFBP5 signaling involving in the regulations of AKT and MAP kinases.
Shadowed shapes represent the EGCG targeted genes. Dashed lines
represent the indirect interactions. The arrows represent the interaction
directions.
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